Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Asia Pacific RNA-Based Therapeutics Market by TECHNOLOGY (Enabling technologies, Microarrays, Labelling, Purification, Linear amplification, QRT-PCR, Inhibition, Enabled technologies, RNA Interference (RNAi) technologies, Small interfering RNA (siRNA), MicroRNA (miRNA), RNA antisense technologies), by APPLICATIONS (Cardiovascular, Kidney diseases, Oncology, Infectious diseases, Metabolic disorders, Others) and by END USERS (Research, Therapeutics, Diagnosis): Global Opportunity Analysis and Industry Forecast, 2023-2032

A01035

Pages: NA

Charts: NA

Tables: NA

The RNA-based therapeutics involves broad range of the RNA-based technologies, which help the patients to diagnose or treat various chronic diseases. The RNA-based therapeutics play a crucial role in providing the accurate and precise healthcare treatments, which helps in treating the disease at molecular and sub-molecular levels. RNA-based therapeutic modalities provide beneficial business opportunities due to its rising acceptance, technological advancements and targeted drug delivery of these therapeutics as compared to the other treatment modalities (synthetic therapeutics). The Asia-Pacific RNA-based therapeutics market is growing at a promising CAGR due to the gene silencing potential of these therapeutics. However, the market is still at the nascent stage in developing regions such as India and witnessing the lucrative growth rate during the analysis period. Factors that would fuel the market growth in Asia-Pacific region are target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, high cost coupled with the high failure rates and reimbursement issues related with the adoption of RNA-based therapeutics would restrain the market growth.

The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end user and geography. Based on technology, the market is segmented into enabling technologies, enabled technologies and RNA antisense technologies. Owing to the applications, the market is segmented into cardiovascular diseases, kidney diseases, oncology infectious diseases and metabolic disorders. Based on the end users, the market is categorized into diagnostic, therapeutic and research organizations. Geographically, the market is segmented into China, Japan, India, Australia and others. Emerging economies such as India, China, Singapore and Malaysia are the potential geographies for market expansion due to improving healthcare standards. These economies have a large presence of domestic manufacturers of RNA-based therapeutics, which contribute to an increase in the market competition for multinational giants by adopting the strategy of price penetration.

Companies profiled in this report are Genzyme Corporation, Tekmira Pharmaceuticals Corp, Biocon ltd, Nitto Denko Corporation, Alnylam Pharmaceuticals, Inc. Acorda Therapeutics Inc., Arrowhead Research Corporation, Abingworth Life Science, Silence Therapeutics PLC, AstraZeneca Inc., and Catalyst Biosciences.

KEY BENEFITS

  • This report includes extensive coverage of the Asia-Pacific RNA-based therapeutics market including drivers, restraints and opportunities that would help professionals to better understand market behavior
  • Analyzing the current market trends, projections regarding the market potential for the period of 20142021 in terms of value are discussed
  • A comprehensive analysis of device types, end users and geography segments enables the identification of growth opportunities within the Asia-Pacific RNA-based therapeutics market
  • Market attractiveness analysis for the market would provide strategic assistance to decision makers
  • An analysis of strategies used by key leaders within the Asia-Pacific RNA-based therapeutics market would prove to be informative for professionals in the corporate sector
  • Porters five forces framework examines the competitive structure of Asia-Pacific RNA-based therapeutics market and would be helpful for strategic industry analysis
  • Ease of doing business analysis would help in making strategic business decisions

ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET KEY SEGMENTS

The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end users and geography segments.

BY TECHNOLOGY

  • Enabling technologies
  • Microarrays
  • Labelling
  • Purification
  • Linear amplification
  • QRT-PCR
  • Inhibition
  • Enabled technologies
  • RNA Interference (RNAi) technologies
  • Small interfering RNA (siRNA)
  • MicroRNA (miRNA)
  • RNA antisense technologies

BY APPLICATIONS

  • Cardiovascular
  • Kidney diseases
  • Oncology
  • Infectious diseases
  • Metabolic disorders
  • Others

BY END USERS

  • Research
  • Therapeutics
  • Diagnosis

BY GEOGRAPHY

  • China
  • Japan
  • India
  • Australia
  • Others

 

 Key Market Segments

  • By TECHNOLOGY
    • Enabling technologies
    • Microarrays
    • Labelling
    • Purification
    • Linear amplification
    • QRT-PCR
    • Inhibition
    • Enabled technologies
    • RNA Interference (RNAi) technologies
    • Small interfering RNA (siRNA)
    • MicroRNA (miRNA)
    • RNA antisense technologies
  • By APPLICATIONS
    • Cardiovascular
    • Kidney diseases
    • Oncology
    • Infectious diseases
    • Metabolic disorders
    • Others
  • By END USERS
    • Research
    • Therapeutics
    • Diagnosis
  • By Region
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • Rest of Asia-Pacific

 
Key Market Players

  • Nitto Denko Corporation
  • Genzyme Corporation
  • Biocon ltd
  • Acorda Therapeutics Inc.
  • Silence Therapeutics PLC
  • Arrowhead Research Corporation
  • Abingworth Life Science
  • Catalyst Biosciences.
  • Alnylam Pharmaceuticals, Inc.
  • Tekmira Pharmaceuticals Corp
  • AstraZeneca Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET, BY TECHNOLOGY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Technology

    • 4.2. Enabling Technologies

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Microarrays

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Labelling

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Purification

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Linear Amplification

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. QRT-PCR

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Inhibition

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Enabled Technologies

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. RNA Interference (RNAi) Technologies

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Small Interfering RNA (siRNA)

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

    • 4.12. MicroRNA (miRNA)

      • 4.12.1. Key Market Trends, Growth Factors and Opportunities

      • 4.12.2. Market Size and Forecast, By Region

      • 4.12.3. Market Share Analysis, By Country

    • 4.13. RNA Antisense Technologies

      • 4.13.1. Key Market Trends, Growth Factors and Opportunities

      • 4.13.2. Market Size and Forecast, By Region

      • 4.13.3. Market Share Analysis, By Country

  • CHAPTER 5: ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET, BY APPLICATIONS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Applications

    • 5.2. Cardiovascular

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Kidney Diseases

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Oncology

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Infectious Diseases

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Metabolic Disorders

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Others

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET, BY END USERS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End Users

    • 6.2. Research

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Therapeutics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Diagnosis

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Technology

      • 7.2.3. Market Size and Forecast, By Applications

      • 7.2.4. Market Size and Forecast, By End Users

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S.

        • 7.2.6.1 Market size and forecast, technology

        • 7.2.6.2 Market size and forecast, applications

        • 7.2.6.3 Market size and forecast, end users

      • 7.2.7. Canada

        • 7.2.7.1 Market size and forecast, technology

        • 7.2.7.2 Market size and forecast, applications

        • 7.2.7.3 Market size and forecast, end users

      • 7.2.8. Mexico

        • 7.2.8.1 Market size and forecast, technology

        • 7.2.8.2 Market size and forecast, applications

        • 7.2.8.3 Market size and forecast, end users

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Technology

      • 7.3.3. Market Size and Forecast, By Applications

      • 7.3.4. Market Size and Forecast, By End Users

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France

        • 7.3.6.1 Market size and forecast, technology

        • 7.3.6.2 Market size and forecast, applications

        • 7.3.6.3 Market size and forecast, end users

      • 7.3.7. Germany

        • 7.3.7.1 Market size and forecast, technology

        • 7.3.7.2 Market size and forecast, applications

        • 7.3.7.3 Market size and forecast, end users

      • 7.3.8. Italy

        • 7.3.8.1 Market size and forecast, technology

        • 7.3.8.2 Market size and forecast, applications

        • 7.3.8.3 Market size and forecast, end users

      • 7.3.9. Spain

        • 7.3.9.1 Market size and forecast, technology

        • 7.3.9.2 Market size and forecast, applications

        • 7.3.9.3 Market size and forecast, end users

      • 7.3.10. UK

        • 7.3.10.1 Market size and forecast, technology

        • 7.3.10.2 Market size and forecast, applications

        • 7.3.10.3 Market size and forecast, end users

      • 7.3.11. Russia

        • 7.3.11.1 Market size and forecast, technology

        • 7.3.11.2 Market size and forecast, applications

        • 7.3.11.3 Market size and forecast, end users

      • 7.3.12. Rest Of Europe

        • 7.3.12.1 Market size and forecast, technology

        • 7.3.12.2 Market size and forecast, applications

        • 7.3.12.3 Market size and forecast, end users

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Technology

      • 7.4.3. Market Size and Forecast, By Applications

      • 7.4.4. Market Size and Forecast, By End Users

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China

        • 7.4.6.1 Market size and forecast, technology

        • 7.4.6.2 Market size and forecast, applications

        • 7.4.6.3 Market size and forecast, end users

      • 7.4.7. Japan

        • 7.4.7.1 Market size and forecast, technology

        • 7.4.7.2 Market size and forecast, applications

        • 7.4.7.3 Market size and forecast, end users

      • 7.4.8. India

        • 7.4.8.1 Market size and forecast, technology

        • 7.4.8.2 Market size and forecast, applications

        • 7.4.8.3 Market size and forecast, end users

      • 7.4.9. South Korea

        • 7.4.9.1 Market size and forecast, technology

        • 7.4.9.2 Market size and forecast, applications

        • 7.4.9.3 Market size and forecast, end users

      • 7.4.10. Australia

        • 7.4.10.1 Market size and forecast, technology

        • 7.4.10.2 Market size and forecast, applications

        • 7.4.10.3 Market size and forecast, end users

      • 7.4.11. Thailand

        • 7.4.11.1 Market size and forecast, technology

        • 7.4.11.2 Market size and forecast, applications

        • 7.4.11.3 Market size and forecast, end users

      • 7.4.12. Malaysia

        • 7.4.12.1 Market size and forecast, technology

        • 7.4.12.2 Market size and forecast, applications

        • 7.4.12.3 Market size and forecast, end users

      • 7.4.13. Indonesia

        • 7.4.13.1 Market size and forecast, technology

        • 7.4.13.2 Market size and forecast, applications

        • 7.4.13.3 Market size and forecast, end users

      • 7.4.14. Rest of Asia Pacific

        • 7.4.14.1 Market size and forecast, technology

        • 7.4.14.2 Market size and forecast, applications

        • 7.4.14.3 Market size and forecast, end users

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Technology

      • 7.5.3. Market Size and Forecast, By Applications

      • 7.5.4. Market Size and Forecast, By End Users

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil

        • 7.5.6.1 Market size and forecast, technology

        • 7.5.6.2 Market size and forecast, applications

        • 7.5.6.3 Market size and forecast, end users

      • 7.5.7. South Africa

        • 7.5.7.1 Market size and forecast, technology

        • 7.5.7.2 Market size and forecast, applications

        • 7.5.7.3 Market size and forecast, end users

      • 7.5.8. Saudi Arabia

        • 7.5.8.1 Market size and forecast, technology

        • 7.5.8.2 Market size and forecast, applications

        • 7.5.8.3 Market size and forecast, end users

      • 7.5.9. UAE

        • 7.5.9.1 Market size and forecast, technology

        • 7.5.9.2 Market size and forecast, applications

        • 7.5.9.3 Market size and forecast, end users

      • 7.5.10. Argentina

        • 7.5.10.1 Market size and forecast, technology

        • 7.5.10.2 Market size and forecast, applications

        • 7.5.10.3 Market size and forecast, end users

      • 7.5.11. Rest of LAMEA

        • 7.5.11.1 Market size and forecast, technology

        • 7.5.11.2 Market size and forecast, applications

        • 7.5.11.3 Market size and forecast, end users

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Genzyme Corporation

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Tekmira Pharmaceuticals Corp

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Biocon Ltd

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Nitto Denko Corporation

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Alnylam Pharmaceuticals, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Acorda Therapeutics Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Arrowhead Research Corporation

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Abingworth Life Science

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Silence Therapeutics PLC

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. AstraZeneca Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Catalyst Biosciences.

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 2. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR ENABLING TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR MICROARRAYS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR LABELLING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR PURIFICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR LINEAR AMPLIFICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR QRT-PCR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR INHIBITION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR ENABLED TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR SMALL INTERFERING RNA (SIRNA), BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR MICRORNA (MIRNA), BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR RNA ANTISENSE TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 15. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR CARDIOVASCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR KIDNEY DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR ONCOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR METABOLIC DISORDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 22. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR RESEARCH, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 29. NORTH AMERICA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. U.S. ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 31. U.S. ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 32. U.S. ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 33. CANADA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 34. CANADA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 35. CANADA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 49. ITALY ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 50. ITALY ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 51. ITALY ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 55. UK ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 56. UK ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 57. UK ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC ASIA PACIFIC RNA-BASED THERAPEUTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 68. CHINA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 69. CHINA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 70. CHINA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 74. INDIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 75. INDIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 76. INDIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 77. SOUTH KOREA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 78. SOUTH KOREA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 79. SOUTH KOREA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 80. AUSTRALIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 81. AUSTRALIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 82. AUSTRALIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 83. THAILAND ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 84. THAILAND ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 85. THAILAND ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 86. MALAYSIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 87. MALAYSIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 88. MALAYSIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 89. INDONESIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 90. INDONESIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 91. INDONESIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA PACIFIC ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA PACIFIC ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 94. REST OF ASIA PACIFIC ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 99. BRAZIL ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 101. BRAZIL ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 102. SOUTH AFRICA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 103. SOUTH AFRICA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 104. SOUTH AFRICA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 107. SAUDI ARABIA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 108. UAE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 109. UAE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 110. UAE ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 111. ARGENTINA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 112. ARGENTINA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 113. ARGENTINA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 116. REST OF LAMEA ASIA PACIFIC RNA-BASED THERAPEUTICS, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 117. GENZYME CORPORATION: KEY EXECUTIVES
  • TABLE 118. GENZYME CORPORATION: COMPANY SNAPSHOT
  • TABLE 119. GENZYME CORPORATION: OPERATING SEGMENTS
  • TABLE 120. GENZYME CORPORATION: PRODUCT PORTFOLIO
  • TABLE 121. GENZYME CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. TEKMIRA PHARMACEUTICALS CORP: KEY EXECUTIVES
  • TABLE 123. TEKMIRA PHARMACEUTICALS CORP: COMPANY SNAPSHOT
  • TABLE 124. TEKMIRA PHARMACEUTICALS CORP: OPERATING SEGMENTS
  • TABLE 125. TEKMIRA PHARMACEUTICALS CORP: PRODUCT PORTFOLIO
  • TABLE 126. TEKMIRA PHARMACEUTICALS CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. BIOCON LTD: KEY EXECUTIVES
  • TABLE 128. BIOCON LTD: COMPANY SNAPSHOT
  • TABLE 129. BIOCON LTD: OPERATING SEGMENTS
  • TABLE 130. BIOCON LTD: PRODUCT PORTFOLIO
  • TABLE 131. BIOCON LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. NITTO DENKO CORPORATION: KEY EXECUTIVES
  • TABLE 133. NITTO DENKO CORPORATION: COMPANY SNAPSHOT
  • TABLE 134. NITTO DENKO CORPORATION: OPERATING SEGMENTS
  • TABLE 135. NITTO DENKO CORPORATION: PRODUCT PORTFOLIO
  • TABLE 136. NITTO DENKO CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. ALNYLAM PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 138. ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 139. ALNYLAM PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 140. ALNYLAM PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 141. ALNYLAM PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. ACORDA THERAPEUTICS INC.: KEY EXECUTIVES
  • TABLE 143. ACORDA THERAPEUTICS INC.: COMPANY SNAPSHOT
  • TABLE 144. ACORDA THERAPEUTICS INC.: OPERATING SEGMENTS
  • TABLE 145. ACORDA THERAPEUTICS INC.: PRODUCT PORTFOLIO
  • TABLE 146. ACORDA THERAPEUTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. ARROWHEAD RESEARCH CORPORATION: KEY EXECUTIVES
  • TABLE 148. ARROWHEAD RESEARCH CORPORATION: COMPANY SNAPSHOT
  • TABLE 149. ARROWHEAD RESEARCH CORPORATION: OPERATING SEGMENTS
  • TABLE 150. ARROWHEAD RESEARCH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 151. ARROWHEAD RESEARCH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. ABINGWORTH LIFE SCIENCE: KEY EXECUTIVES
  • TABLE 153. ABINGWORTH LIFE SCIENCE: COMPANY SNAPSHOT
  • TABLE 154. ABINGWORTH LIFE SCIENCE: OPERATING SEGMENTS
  • TABLE 155. ABINGWORTH LIFE SCIENCE: PRODUCT PORTFOLIO
  • TABLE 156. ABINGWORTH LIFE SCIENCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. SILENCE THERAPEUTICS PLC: KEY EXECUTIVES
  • TABLE 158. SILENCE THERAPEUTICS PLC: COMPANY SNAPSHOT
  • TABLE 159. SILENCE THERAPEUTICS PLC: OPERATING SEGMENTS
  • TABLE 160. SILENCE THERAPEUTICS PLC: PRODUCT PORTFOLIO
  • TABLE 161. SILENCE THERAPEUTICS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. ASTRAZENECA INC.: KEY EXECUTIVES
  • TABLE 163. ASTRAZENECA INC.: COMPANY SNAPSHOT
  • TABLE 164. ASTRAZENECA INC.: OPERATING SEGMENTS
  • TABLE 165. ASTRAZENECA INC.: PRODUCT PORTFOLIO
  • TABLE 166. ASTRAZENECA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. CATALYST BIOSCIENCES.: KEY EXECUTIVES
  • TABLE 168. CATALYST BIOSCIENCES.: COMPANY SNAPSHOT
  • TABLE 169. CATALYST BIOSCIENCES.: OPERATING SEGMENTS
  • TABLE 170. CATALYST BIOSCIENCES.: PRODUCT PORTFOLIO
  • TABLE 171. CATALYST BIOSCIENCES.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET
  • FIGURE 3. SEGMENTATION ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALASIA PACIFIC RNA-BASED THERAPEUTICS MARKET
  • FIGURE 11. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET SEGMENTATION, BY TECHNOLOGY
  • FIGURE 12. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR ENABLING TECHNOLOGIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR LABELLING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR PURIFICATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR LINEAR AMPLIFICATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR QRT-PCR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR INHIBITION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR ENABLED TECHNOLOGIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) TECHNOLOGIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR SMALL INTERFERING RNA (SIRNA), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR MICRORNA (MIRNA), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR RNA ANTISENSE TECHNOLOGIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET SEGMENTATION, BY APPLICATIONS
  • FIGURE 25. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR CARDIOVASCULAR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR KIDNEY DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET SEGMENTATION, BY END USERS
  • FIGURE 32. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR RESEARCH, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR THERAPEUTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 34. ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET FOR DIAGNOSIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 35. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 38. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 39. COMPETITIVE DASHBOARD
  • FIGURE 40. COMPETITIVE HEATMAP: ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET
  • FIGURE 41. TOP PLAYER POSITIONING,2022
  • FIGURE 42. GENZYME CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. GENZYME CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. GENZYME CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. TEKMIRA PHARMACEUTICALS CORP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. TEKMIRA PHARMACEUTICALS CORP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. TEKMIRA PHARMACEUTICALS CORP: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. BIOCON LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BIOCON LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. BIOCON LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. NITTO DENKO CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. NITTO DENKO CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. NITTO DENKO CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. ALNYLAM PHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. ALNYLAM PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. ALNYLAM PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. ACORDA THERAPEUTICS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. ACORDA THERAPEUTICS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. ACORDA THERAPEUTICS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. ARROWHEAD RESEARCH CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. ARROWHEAD RESEARCH CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. ARROWHEAD RESEARCH CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. ABINGWORTH LIFE SCIENCE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. ABINGWORTH LIFE SCIENCE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. ABINGWORTH LIFE SCIENCE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 66. SILENCE THERAPEUTICS PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. SILENCE THERAPEUTICS PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 68. SILENCE THERAPEUTICS PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 69. ASTRAZENECA INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. ASTRAZENECA INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 71. ASTRAZENECA INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 72. CATALYST BIOSCIENCES.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. CATALYST BIOSCIENCES.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 74. CATALYST BIOSCIENCES.: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
Asia Pacific RNA-Based Therapeutics Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved